SEHK:2186Pharmaceuticals
Luye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision
Why Luye Pharma’s latest earnings matter for investors
Luye Pharma Group (SEHK:2186) has drawn fresh attention after reporting its full year 2025 results, with higher sales and net income alongside a decision not to declare a 2025 dividend.
The company reported sales of CN¥6,308.37 million for 2025, compared with CN¥6,061.44 million a year earlier. Net income came in at CN¥618.75 million, up from CN¥471.89 million, while basic earnings per share from continuing operations were CN¥0.1588...